{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:48:33Z","timestamp":1788400113001,"version":"build-2803163510"},"reference-count":395,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.phrs.2025.107727","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T02:11:20Z","timestamp":1746151880000},"page":"107727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["IUPHAR review: Moving beyond dopamine-based therapeutic strategies for schizophrenia"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6655-4784","authenticated-orcid":false,"given":"Paula M.","family":"Moran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiri T.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.phrs.2025.107727_bib1","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.phrs.2025.107727_bib2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","article-title":"Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia","volume":"137","author":"Wallwork","year":"2012","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107727_bib3","first-page":"1","volume":"264","author":"Tandon","year":"2024"},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/wps.20959","article-title":"The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics","volume":"21","author":"Fusar-Poli","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.schres.2022.07.005","article-title":"Are these my thoughts?\u2019: a 20-year prospective study of thought insertion, thought withdrawal, thought broadcasting, and their relationship to auditory verbal hallucinations","volume":"265","author":"L\u00f3pez-Silva","year":"2024","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107727_bib6","article-title":"Substance-Induced Psychoses: An Updated Literature Review","volume":"12","author":"Fiorentini","year":"2021"},{"key":"10.1016\/j.phrs.2025.107727_bib7","first-page":"131","article-title":"Psychosis in Alzheimer disease \u2014 mechanisms, genetics and therapeutic opportunities","volume":"18","author":"Ismail","year":"2022"},{"key":"10.1016\/j.phrs.2025.107727_bib8","first-page":"71","volume":"258","author":"Marder","year":"2023"},{"key":"10.1016\/j.phrs.2025.107727_bib9","series-title":"Essentials of schizophrenia","first-page":"73","article-title":"Neurocognitive Impairments","author":"Keefe","year":"2012"},{"issue":"5","key":"10.1016\/j.phrs.2025.107727_bib10","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib11","author":"Green","year":"2006","journal-title":"Cogn. Impair. Funct. Outcome Schizophr. Bipolar Disord."},{"issue":"11","key":"10.1016\/j.phrs.2025.107727_bib12","volume":"5","author":"Kotov","year":"2021","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.phrs.2025.107727_bib13","article-title":"Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions","volume":"40","author":"Yung","year":"2006","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib14","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-11-126","article-title":"Toward the future of psychiatric diagnosis: The seven pillars of RDoC","volume":"11","author":"Cuthbert","year":"2013","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000501797","article-title":"Research domain criteria: strengths, weaknesses, and potential alternatives for future psychiatric research","volume":"5","author":"Ross","year":"2019","journal-title":"Complex Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib16","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02414-0","article-title":"Revisiting the seven pillars of RDoC","volume":"20","author":"Morris","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.phrs.2025.107727_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1068\/p3403ed","article-title":"The original spin doctors--the meeting of perception and insanity","volume":"34","author":"Wade","year":"2005","journal-title":"Perception"},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1192\/bjb.2022.45","article-title":"Madness and society in Britain","volume":"47","author":"Ikkos","year":"2023","journal-title":"BJPsych Bull."},{"issue":"21","key":"10.1016\/j.phrs.2025.107727_bib19","first-page":"112","article-title":"Utilisation en th\u00e9rapeutique psychiatrique d\u2019une ph\u00e9nothiazine d\u2019action centrale \u00e9lective (4560 RP) [Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)","volume":"110","author":"Delay","year":"1952","journal-title":"Ann. Med Psychol. (Paris)"},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib20","first-page":"492","article-title":"The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs","volume":"160","author":"Van Rossum","year":"1966","journal-title":"Arch. Int Pharm. Ther."},{"issue":"4238","key":"10.1016\/j.phrs.2025.107727_bib21","first-page":"481","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science (1979)"},{"issue":"5","key":"10.1016\/j.phrs.2025.107727_bib22","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/JCP.0b013e3182979a0a","article-title":"Estimated dopamine D2 receptor occupancy and remission in schizophrenia: analysis of the catie data","volume":"33","author":"Moriguchi","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107727_bib23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","article-title":"Estimating dopamine d2 receptor occupancy for doses of 8 antipsychotics: a meta-analysis","volume":"33","author":"Lako","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107727_bib24","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/277093a0","article-title":"review article multiple receptors for dopamine","volume":"277","author":"Kebabian","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107727_bib26","volume":"28","author":"Granger","year":"2023"},{"issue":"8","key":"10.1016\/j.phrs.2025.107727_bib27","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1176\/appi.ajp.2011.11010039","article-title":"the NIMH-CATIE Schizophrenia study: what did we learn?","volume":"168","author":"Lieberman","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1023\/A:1020464017021","article-title":"Safety and tolerability: How do newer generation \u201cAtypical\u201d antipsychotics compare?","volume":"73","author":"Tandon","year":"2002","journal-title":"Psychiatr. Q"},{"key":"10.1016\/j.phrs.2025.107727_bib29","doi-asserted-by":"crossref","DOI":"10.2174\/138161210790361461","article-title":"Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?","volume":"16","author":"Mailman","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2025.107727_bib30","doi-asserted-by":"crossref","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists a new class of antipsychotic","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2025.107727_bib31","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.159.2.180","article-title":"Reviews and overviews amisulpride, an unusual \u201catypical\u201d antipsychotic: a meta-analysis of randomized controlled trials","volume":"159","author":"Leucht","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.phrs.2025.107727_bib32","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/schbul\/2.1.19","article-title":"dopamine hypothesis","volume":"2","author":"Meltzer","year":"1976","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107727_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1076\/jhin.11.3.265.10391","article-title":"Historical development of the dopamine hypothesis of schizophrenia","author":"Baumeister","year":"2002","journal-title":": J. Hist. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III - The final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"17","key":"10.1016\/j.phrs.2025.107727_bib36","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","article-title":"Single photon emission computerized tomography imaging of amphetamine-induced dopamine. release in drug-free schizophrenic subjects","volume":"93","author":"Laruelle","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2025.107727_bib37","author":"Laruelle","year":"1999","journal-title":"Increase Dopamine Transm. Schizophr.: Relatsh. Illn. Phases"},{"issue":"14","key":"10.1016\/j.phrs.2025.107727_bib38","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","article-title":"Increased baseline occupancy of D2 receptors by dopamine in schizophrenia","volume":"97","author":"Abi-Dargham","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2025.107727_bib39","first-page":"501","article-title":"Integrating the Neurodevelopmental and Dopamine Hypotheses of Schizophrenia and the Role of Cortical Excitation-Inhibition Balance","volume":"92","author":"Howes","year":"2022"},{"issue":"6","key":"10.1016\/j.phrs.2025.107727_bib40","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0022-3956(99)00033-3","article-title":"Development, disease and degeneration in schizophrenia: a unitary pathophysiological model","volume":"33","author":"Keshavan","year":"1999","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.phrs.2025.107727_bib41","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/schbul\/sbn187","article-title":"The neurodevelopmental hypothesis of Schizophrenia, revisited","volume":"35","author":"Fatemi","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107727_bib42","first-page":"611","article-title":"Schizophrenia genomics: genetic complexity and functional insights","volume":"25","author":"Sullivan","year":"2024"},{"key":"10.1016\/j.phrs.2025.107727_bib43","first-page":"1843","article-title":"The synaptic hypothesis of schizophrenia version III: a master mechanism","volume":"28","author":"Howes","year":"2023"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"Mccutcheon","year":"2020","journal-title":"World J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbr.2007.12.006","article-title":"Cognitive dysfunction in neuropsychiatric disorders: Selected serotonin receptor subtypes as therapeutic targets","volume":"195","author":"Terry","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2025.107727_bib46","article-title":"Dynamic functional connectivity in schizophrenia and bipolar disorder: A review of the evidence and associations with psychopathological features","volume":"127","author":"Cattarinussi","year":"2023"},{"key":"10.1016\/j.phrs.2025.107727_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2019.101805","article-title":"Default mode network connectivity is associated with long-term clinical outcome in patients with schizophrenia","volume":"22","author":"Lee","year":"2019","journal-title":"Neuroimage Clin."},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib48","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/npp.2009.192","article-title":"Treatment with olanzapine is associated with modulation of the default mode network in patients with schizophrenia","volume":"35","author":"Sambataro","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-neuro-100223-121214","article-title":"Predictive Processing: A Circuit Approach to Psychosis","volume":"47","author":"Keller","year":"2024","journal-title":"Annu Rev Neurosci"},{"issue":"7906","key":"10.1016\/j.phrs.2025.107727_bib50","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","article-title":"Mapping genomic loci implicates genes and synaptic biology in schizophrenia","volume":"604","author":"Trubetskoy","year":"2022","journal-title":"Nature"},{"issue":"7906","key":"10.1016\/j.phrs.2025.107727_bib51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","article-title":"Rare coding variants in ten genes confer substantial risk for schizophrenia","volume":"604","author":"Singh","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107727_bib52","article-title":"Exploring causal mechanisms of psychosis risk","volume":"162","author":"Oliver","year":"2024"},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib53","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1192\/bjp.2024.65","article-title":"Towards a unified theory of the aetiology of schizophrenia","volume":"225","author":"Jiang","year":"2024","journal-title":"Br. J. Psychiatry [Internet]"},{"issue":"6842","key":"10.1016\/j.phrs.2025.107727_bib54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/35083500","volume":"412","author":"Waelti","year":"2001","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.phrs.2025.107727_bib55","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1172\/JCI18533","article-title":"The addicted human brain: insights from imaging studies","volume":"111","author":"Volkow","year":"2003","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.phrs.2025.107727_bib56","series-title":"In: Neuroscience and Biobehavioral Reviews","first-page":"765","article-title":"Ventral striatal control of appetitive motivation: Role in ingestive behavior and reward-related learning","author":"Kelley","year":"2004"},{"key":"10.1016\/j.phrs.2025.107727_bib57","first-page":"524","article-title":"Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression","volume":"17","author":"Grace","year":"2016"},{"issue":"10","key":"10.1016\/j.phrs.2025.107727_bib58","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/nn.4377","article-title":"VTA dopaminergic neurons regulate ethologically relevant sleep-wake behaviors","volume":"19","author":"Eban-Rothschild","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-psych-020223-012208","article-title":"The neurobiology of activational aspects of motivation: exertion of effort, effort-based decision making, and the role of dopamine","volume":"75","author":"Salamone","year":"2024","journal-title":"Annu Rev. Psychol."},{"key":"10.1016\/j.phrs.2025.107727_bib60","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bph.12906","article-title":"NC-IUPHAR REVIEW","volume":"172","author":"Beaulieu","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1017\/S003329170003960X","article-title":"The pathophysiology of extrapyramidal side-effects of neuroleptic drugs","volume":"10","author":"Marsden","year":"1980","journal-title":"Psychol. Med"},{"key":"10.1016\/j.phrs.2025.107727_bib63","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib64","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0033-3182(85)72863-0","volume":"26","author":"Yassa","year":"1985","journal-title":"Psychosom."},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib65","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/wps.20579","article-title":"Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis","volume":"17","author":"Carbon","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib66","article-title":"Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders","volume":"2017","author":"Dold","year":"2015"},{"issue":"7273","key":"10.1016\/j.phrs.2025.107727_bib67","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"A typical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"B.M.J"},{"key":"10.1016\/j.phrs.2025.107727_bib68","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Article double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study","volume":"165","author":"Sikich","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib69","doi-asserted-by":"crossref","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Article effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the BritisH Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.phrs.2025.107727_bib71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2011.06.008","article-title":"Life expectancy among persons with schizophrenia or bipolar affective disorder","volume":"131","author":"Laursen","year":"2011","journal-title":"Schizophr. Res"},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib72","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2014.00137","article-title":"Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes and interventions","volume":"5","author":"Ringen","year":"2014","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib74","series-title":"A guide to the extrapyramidal side-effects of antipsychotic drugs","author":"Owens","year":"2014"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jamapsychiatry.2024.2890","article-title":"Antipsychotic drugs and cognitive function: a systematic review and pairwise network meta-analysis","volume":"82","author":"Feber","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"10202","key":"10.1016\/j.phrs.2025.107727_bib76","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107727_bib77","first-page":"58","article-title":"Treatment resistance in psychiatry: state of the art and new directions","volume":"27","author":"Howes","year":"2022"},{"key":"10.1016\/j.phrs.2025.107727_bib78","first-page":"167","article-title":"Impact of a five-dimensional framework on R&D productivity at AstraZeneca","volume":"17","author":"Morgan","year":"2018"},{"issue":"6","key":"10.1016\/j.phrs.2025.107727_bib79","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00213-021-05787-x","article-title":"Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology","volume":"238","author":"Tricklebank","year":"2012","journal-title":"Psychopharmacology (Berl.)."},{"key":"10.1016\/j.phrs.2025.107727_bib80","volume":"30","author":"Loiodice","year":"2025"},{"key":"10.1016\/j.phrs.2025.107727_bib81","volume":"333","author":"Torrey","year":"2024"},{"key":"10.1016\/j.phrs.2025.107727_bib82","series-title":"Hoopla and disappointment","author":"Wade","year":"2009"},{"issue":"8","key":"10.1016\/j.phrs.2025.107727_bib83","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia A randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib84","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/d41573-024-00129-w","article-title":"Muscarinic drugs breathe new life into schizophrenia pipeline","volume":"23","author":"Kingwell","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2025.107727_bib85","volume":"28","author":"Granger","year":"2023"},{"key":"10.1016\/j.phrs.2025.107727_bib86","first-page":"2179","article-title":"Advances in the study of cholinergic circuits in the central nervous system","volume":"10","author":"He","year":"2023"},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib87","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0031-6997(24)01362-0","article-title":"International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors","volume":"50","author":"Caulfield","year":"1998","journal-title":"Pharm. Rev."},{"issue":"26","key":"10.1016\/j.phrs.2025.107727_bib88","doi-asserted-by":"crossref","first-page":"8124","DOI":"10.1073\/pnas.1508846112","article-title":"Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens","volume":"112","author":"Shin","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107727_bib89","first-page":"183","volume":"10","author":"Foster","year":"2014"},{"key":"10.1016\/j.phrs.2025.107727_bib90","first-page":"431","volume":"94","author":"Foster","year":"2017"},{"key":"10.1016\/j.phrs.2025.107727_bib91","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1006\/brcg.1995.1255","article-title":"Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in huma consciousness","volume":"28","author":"Perry","year":"1985","journal-title":"Brain Cogn."},{"key":"10.1016\/j.phrs.2025.107727_bib92","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.conb.2006.09.002","article-title":"The role of acetylcholine in learning and memory","volume":"16","author":"Hasselmo","year":"2006","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.phrs.2025.107727_bib93","first-page":"231","volume":"33","author":"Blokland","year":"2022"},{"key":"10.1016\/j.phrs.2025.107727_bib94","series-title":"In: Annals of the New York Academy of Sciences","first-page":"225","article-title":"Cholinergic mediation of attention: Contributions of phasic and tonic increases in prefrontal cholinergic activity","author":"Parikh","year":"2008"},{"key":"10.1016\/j.phrs.2025.107727_bib95","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","article-title":"Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior","volume":"76","author":"Picciotto","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2025.107727_bib96","first-page":"1917","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018"},{"key":"10.1016\/j.phrs.2025.107727_bib97","first-page":"397","article-title":"Focal acetylcholinergic modulation of the human midcingulo-insular network during attention: Meta-analytic neuroimaging and behavioral evidence","volume":"168","author":"Chakraborty","year":"2024"},{"issue":"7 July","key":"10.1016\/j.phrs.2025.107727_bib98","article-title":"Dopamine and acetylcholine have distinct roles in delay- and effort-based decision-making in humans","volume":"22","author":"Abdoust","year":"2024","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2025.107727_bib99","article-title":"A role for acetylcholine in reinforcement learning and decision making under uncertainty. [Internet]","author":"Kurtenbach","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.phrs.2025.107727_bib100","volume":"93","author":"Levey","year":"1996","journal-title":"Colloq. Pap. This Pap. was Presente a Colloq. Entitled \u2019 \u2019Mem.: Rec. Exp. Cells Circuits [Internet]"},{"issue":"10","key":"10.1016\/j.phrs.2025.107727_bib101","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.biopsych.2006.08.050","article-title":"Altered hippocampal muscarinic M4, but Not M1, receptor expression from subjects with schizophrenia","volume":"61","author":"Scarr","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.phrs.2025.107727_bib102","first-page":"597","article-title":"Large-scale neurocognitive networks and distributed processing for attention, language and memory","volume":"28","author":"Mesulam","year":"1990","journal-title":"Neurol. Prog."},{"issue":"10","key":"10.1016\/j.phrs.2025.107727_bib103","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/sj.mp.4001199","article-title":"Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia","volume":"7","author":"Dean","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib104","volume":"210","author":"Dean","year":"2024"},{"issue":"6","key":"10.1016\/j.phrs.2025.107727_bib105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/jnr.20600","article-title":"Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia","volume":"81","author":"Deng","year":"2005","journal-title":"J. Neurosci. Res"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib106","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nn992","article-title":"Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice","volume":"6","author":"Anagnostaras","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib107","series-title":"Animal Models of Cognitive Impairment","article-title":"Muscarinic receptor Antagonists in Rats","author":"Terry","year":"2006"},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib108","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1749-6632.1957.tb40764.x","article-title":"The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain","volume":"66","author":"Pfeiffer","year":"1957","journal-title":"Ann. N. Y Acad. Sci."},{"key":"10.1016\/j.phrs.2025.107727_bib109","first-page":"611","article-title":"Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia","volume":"179","author":"Paul","year":"2022"},{"key":"10.1016\/j.phrs.2025.107727_bib110","article-title":"The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia","volume":"15","author":"Yohn","year":"2024"},{"issue":"12","key":"10.1016\/j.phrs.2025.107727_bib111","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1096\/fj.04-1575fje","article-title":"M 4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies","volume":"18","author":"Tzavara","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2025.107727_bib112","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.brainresrev.2008.02.003","article-title":"Cholinergic modulation of midbrain dopaminergic systems","volume":"58","author":"Mena-Segovia","year":"2008","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.phrs.2025.107727_bib113","first-page":"341","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018"},{"key":"10.1016\/j.phrs.2025.107727_bib114","volume":"258","author":"Kaoullas","year":"2024"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3565(25)38667-2","article-title":"Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors","volume":"269","author":"Shannon","year":"1994","journal-title":"J. Pharmacol. Exp."},{"key":"10.1016\/j.phrs.2025.107727_bib116","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.0.CO;2-K","article-title":"Xanomeline: G selective muscarinic agonist for the treatment of Alzheimer\u2019s disease","volume":"40","author":"Bymaster","year":"1997","journal-title":"Drug Dev. Res."},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib117","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.phrs.2025.107727_bib118","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.phrs.2025.107727_bib119","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107727_bib120","unstructured":"Federal Drug Administration. FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia. September 26th 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-new-mechanism-action-treatment-schizophrenia."},{"key":"10.1016\/j.phrs.2025.107727_bib121","first-page":"183","article-title":"Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer\u2019s disease and schizophrenia","volume":"10","author":"Foster","year":"2014"},{"key":"10.1016\/j.phrs.2025.107727_bib122","first-page":"405","article-title":"Targeting muscarinic receptors to treat schizophrenia","author":"Foster","year":"2021","journal-title":"Behav. Brain Res."},{"issue":"9","key":"10.1016\/j.phrs.2025.107727_bib123","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1523\/JNEUROSCI.5620-09.2010","article-title":"Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum","volume":"30","author":"Threlfell","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib124","first-page":"1098","article-title":"Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic","volume":"43","author":"Yohn","year":"2022"},{"key":"10.1016\/j.phrs.2025.107727_bib125","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-pharmtox-051921-023858","article-title":"Targeting the actions of muscarinic receptors on dopamine systems: new strategies for treating neuropsychiatric disorders","volume":"64","author":"Nunes","year":"2024","journal-title":"Annu Rev. Pharm. Toxicol"},{"issue":"7979","key":"10.1016\/j.phrs.2025.107727_bib126","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41586-023-06492-9","article-title":"Dopamine and glutamate regulate striatal acetylcholine in decision-making","volume":"621","author":"Chantranupong","year":"2023","journal-title":"Nature"},{"issue":"10369","key":"10.1016\/j.phrs.2025.107727_bib127","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","article-title":"Articles Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, doubleblind, placebo-controlled, phase 1b trial","volume":"400","author":"Krystal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107727_bib128","unstructured":"AbbVie. AbbVie-Provides-Update-on-Phase-2-Results-for-Emraclidine-inSchizophrenia. 2024. https:\/\/news.abbvie.com\/2024-11-11-AbbVie-Provides-Update-on-Phase-2-Results-for-Emraclidine-in-Schizophrenia (retrieved 06\/05\/25)."},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib129","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0166-2236(96)10073-4","article-title":"Presynaptic nicotinic ACh receptors","volume":"20","author":"Wonnacott","year":"1997","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib130","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0166-2236(99)01471-X","article-title":"Nicotinic receptors in the brain: correlating physiology with function","volume":"22","author":"Jones","year":"1999","journal-title":"Trends Neurosci."},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib131","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/neu.10151","article-title":"Nicotinic receptor subtypes and cognitive function","volume":"53","author":"Levin","year":"2002","journal-title":"J. Neurobiol."},{"key":"10.1016\/j.phrs.2025.107727_bib132","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pneurobio.2004.09.006","article-title":"Neuronal nicotinic receptors: from structure to pathology","volume":"74","author":"Gotti","year":"2004","journal-title":"Prog. Neurobiol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib133","article-title":"Nicotinic acetylcholine receptors (nACh) in GtoPdb v.2023.3","volume":"2023","author":"Gotti","year":"2023","journal-title":"IUPHAR\/BPS Guide Pharmacol. CITE"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib134","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1113\/jphysiol.2006.114645","article-title":"Roles of nicotinic acetylcholine receptor \u03b2 subunits in function of human \u03b14-containing nicotinic receptors","volume":"576","author":"Wu","year":"2006","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2025.107727_bib135","volume":"171","author":"Gharpure","year":"2020"},{"key":"10.1016\/j.phrs.2025.107727_bib136","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neuron.2011.03.014","article-title":"Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses","volume":"70","author":"Miwa","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2025.107727_bib137","volume":"204","author":"Abbondanza","year":"2024"},{"key":"10.1016\/j.phrs.2025.107727_bib138","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1021\/jm040219e","article-title":"Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations","volume":"48","author":"Jensen","year":"2005","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.phrs.2025.107727_bib139","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.cell.2021.02.049","article-title":"Structure and gating mechanism of the \u03b17 nicotinic acetylcholine receptor","volume":"184","author":"Noviello","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107727_bib140","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1146\/annurev.pharmtox.47.120505.105214","article-title":"Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system","volume":"47","author":"Dani","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.phrs.2025.107727_bib141","doi-asserted-by":"crossref","unstructured":"Adler L.E., Olincy A., Waldo M., Harris J.Q., Qriffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., Freedman R. Schizophrenia, Sensory Gating, and Nicotinic Receptors. Schizophr Bull. 24(2) (1998) 189-202.","DOI":"10.1093\/oxfordjournals.schbul.a033320"},{"issue":"12","key":"10.1016\/j.phrs.2025.107727_bib142","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archpsyc.59.12.1085","article-title":"Association of Promoter Variants in the 7 Nicotinic Acetylcholine Receptor Subunit Gene With an Inhibitory Deficit Found in","volume":"59","author":"Leonard","year":"2002","journal-title":"Schizophrenia.Archives of general psychiatry."},{"key":"10.1016\/j.phrs.2025.107727_bib143","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1300\/J374v03n03_05","article-title":"Genetics of smoking and schizophrenia","volume":"3","author":"Leonard","year":"2007","journal-title":"J. Dual Diagn."},{"issue":"8","key":"10.1016\/j.phrs.2025.107727_bib144","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1097\/00001756-199906030-00028","article-title":"Decreased protein level of nicotinic receptor \u03b17 subunit in the frontal cortex from schizophrenic brain","volume":"10","author":"Guan","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.phrs.2025.107727_bib145","author":"Freedman","year":"1995","journal-title":"Evid. Post. Brain Tissue Decreased Numbers Hippocampal Nicotinic Recept. Schizophr."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib146","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/1096-8628(20010108)105:1<20::AID-AJMG1047>3.0.CO;2-C","article-title":"Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7)","volume":"105","author":"Freedman","year":"2001","journal-title":"Am. J. Med Genet"},{"key":"10.1016\/j.phrs.2025.107727_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2009.07.041","article-title":"A 2-base pair deletion polymorphism in the partial duplication of the \u03b17 nicotinic acetylcholine gene (CHRFAM7A) on chromosome 15q14 is associated with schizophrenia","volume":"1291","author":"Sinkus","year":"2009","journal-title":"Brain Res"},{"issue":"1\u20133","key":"10.1016\/j.phrs.2025.107727_bib148","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.schres.2008.12.017","article-title":"Association of the 5\u2032-upstream regulatory region of the \u03b17 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia","volume":"109","author":"Stephens","year":"2009","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107727_bib149","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2013.00133","article-title":"Association of the nicotinic receptor \u03b17 subunit gene (CHRNA7) with schizophrenia and visual backward masking","volume":"4","author":"Bakanidze","year":"2013","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib150","article-title":"Smoking and schizophrenia: abnormal nicotinic receptor expression.","volume":"393 (1-3): 237-42.","author":"Leonard","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2025.107727_bib151","article-title":"Cigarette Smoking and Schizophrenia: Etiology, Clinical, Pharmacological, and Treatment Implications","volume":"2021","author":"Ding","year":"2021"},{"issue":"7","key":"10.1016\/j.phrs.2025.107727_bib152","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00406-022-01410-y","article-title":"Demographics, clinical characteristics and cognitive symptoms of heavy smokers and non-heavy smokers in Chinese male patients with chronic schizophrenia","volume":"272","author":"Wei","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"14","key":"10.1016\/j.phrs.2025.107727_bib153","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1017\/S0033291719002678","article-title":"Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study","volume":"50","author":"Wootton","year":"2020","journal-title":"Psychol. Med"},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib154","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/schbul\/sby093","article-title":"Genome-wide variants shared between smoking quantity and schizophrenia on 15q25 are associated with CHRNA5 expression in the brain","volume":"45","author":"Ohi","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107727_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/S0006-3223(00)01094-5","article-title":"Cognitive effects of nicotine","volume":"49","author":"Rezvani","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib156","first-page":"15","article-title":"Cognitive effects of nicotine: recent progress","author":"Valentine","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.phrs.2025.107727_bib157","article-title":"Nicotine\u2019s effect on cognition, a friend or foe?","volume":"124","author":"Wang","year":"2022"},{"key":"10.1016\/j.phrs.2025.107727_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108053","article-title":"\u03b17 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: update on animal and clinical studies and strategies for the future","volume":"170","author":"Terry","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2025.107727_bib159","first-page":"86","volume":"282","author":"Faure","year":"2014"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib160","first-page":"12","article-title":"Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia","volume":"20","author":"Preskorn","year":"2014","journal-title":"J. Psychiatr. Pr."},{"issue":"13","key":"10.1016\/j.phrs.2025.107727_bib161","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1038\/npp.2015.176","article-title":"Randomized, Double-Blind, Placebo-controlled study of encenicline, an \u03b17 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia","volume":"40","author":"Keefe","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib162","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/14737175.2015.995639","article-title":"Safety and clinical effects of EVP-6124 in subjects with Alzheimer\u2019s disease currently or previously receiving an acetylcholinesterase inhibitor medication","volume":"15","author":"Deardorff","year":"2014","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib163","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-016-0210-1","article-title":"ABT-126 monotherapy in mild-to-moderate Alzheimer\u2019s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension","volume":"8","author":"Gault","year":"2016","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.phrs.2025.107727_bib165","doi-asserted-by":"crossref","unstructured":"Rossell S., Reser M., Bryce S., Contreras N., Tan E., Lee S., Brannan S., Miller A., Felder C., Paul S., Breier A. KARXT: A M1\/M4 Preferring muscarinic agonist for the treatment of schizophrenia. Schizophr Bull April 2019 45 (supplement2) S244-S245 abstract T106.","DOI":"10.1093\/schbul\/sbz019.386"},{"key":"10.1016\/j.phrs.2025.107727_bib166","doi-asserted-by":"crossref","DOI":"10.3389\/fnimg.2024.1358221","article-title":"Characterizing the binding of TC-5619 and encenicline on the alpha7 nicotinic acetylcholine receptor using PET imaging in the pig","volume":"3","author":"Magnussen","year":"2024","journal-title":"Front. Neuroimaging"},{"key":"10.1016\/j.phrs.2025.107727_bib167","article-title":"The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia","volume":"10","author":"Cotter","year":"2019"},{"issue":"39","key":"10.1016\/j.phrs.2025.107727_bib168","doi-asserted-by":"crossref","first-page":"10578","DOI":"10.1523\/JNEUROSCI.2444-07.2007","article-title":"Broad-spectrum efficacy across cognitive domains by \u03b17 nicotinic acetylcholine receptor agonism correlates with activation of ERK1\/2 and CREB phosphorylation pathways","volume":"27","author":"Bitner","year":"2007","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.phrs.2025.107727_bib169","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1038\/npp.2016.101","article-title":"The \u03b17 nicotinic agonist ABT-126 in the treatment of cognitive impairment associated with schizophrenia in nonsmokers: results from a randomized controlled phase 2b study","volume":"41","author":"Haig","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.phrs.2025.107727_bib170","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1176\/appi.ajp.2015.15010093","article-title":"A randomized trial to assess the efficacy and safety of ABT-126, a selective \u03b17 nicotinic acetylcholine receptor agonist, in the treatment of cognitive impairment in schizophrenia","volume":"173","author":"Haig","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib171","doi-asserted-by":"crossref","DOI":"10.1177\/0269881118812097","article-title":"Procognitive effects of varenicline in the animal model of schizophrenia depend on \u03b14\u03b22- and \u03b17-nicotinic acetylcholine receptors","volume":"33","author":"Potasiewicz","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib172","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.nlm.2008.03.002","article-title":"Varenicline ameliorates ethanol-induced deficits in learning in C57BL\/6 mice","volume":"90","author":"Gulick","year":"2008","journal-title":"Neurobiol. Learn. Mem"},{"key":"10.1016\/j.phrs.2025.107727_bib173","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neuropharm.2016.03.025","article-title":"Effects of varenicline on alpha4-containing nicotinic acetylcholine receptor expression and cognitive performance in mice","volume":"107","author":"Lange-Asschenfeldt","year":"2016","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.phrs.2025.107727_bib174","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1037\/a0012601","article-title":"Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL\/6 mice","volume":"122","author":"Raybuck","year":"2008","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib175","first-page":"239","article-title":"Varenicline enhances recognition memory via \u03b17 nicotinic acetylcholine receptors in the medial prefrontal cortex in male mice","author":"Esaki","year":"2023","journal-title":"Neuropharmacology"},{"issue":"1\u20133","key":"10.1016\/j.phrs.2025.107727_bib176","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.schres.2009.02.001","article-title":"Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder","volume":"110","author":"Smith","year":"2009","journal-title":"Schizophr. Res"},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib177","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/npp.2011.238","article-title":"Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial","volume":"37","author":"Shim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107727_bib178","first-page":"562","article-title":"Effects of varenicline on cognitive function in non-smokers with schizophrenia","volume":"197","author":"Kozak","year":"2018"},{"issue":"12","key":"10.1016\/j.phrs.2025.107727_bib179","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2011.83","article-title":"Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder","volume":"68","author":"Hong","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib180","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11033-010-0128-9","article-title":"Glutamate receptors and signal transduction in learning and memory","volume":"38","author":"Peng","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.phrs.2025.107727_bib181","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1744-859X-9-27","article-title":"A randomised, double-blind placebo-controlled trial of tropisetron in pateints with schizophrenia","volume":"9","author":"Shiina","year":"2010","journal-title":"Ann. Gen. Psychiatry"},{"issue":"9","key":"10.1016\/j.phrs.2025.107727_bib182","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1176\/appi.ajp.2012.11081289","article-title":"Short-term tropisetron treatment and cognitive P50 auditory gating deficits in schizophrenia","volume":"169","author":"Zhang","year":"2012","journal-title":"Am. J Psychiatry"},{"issue":"8","key":"10.1016\/j.phrs.2025.107727_bib183","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41386-020-0685-0","article-title":"One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia","volume":"45","author":"Xia","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"36","key":"10.1016\/j.phrs.2025.107727_bib184","first-page":"A35","article-title":"biomarker-drug combination to target cognitive impairment associated with schizophrenia: preclinical findings","volume":"8","author":"Granger","year":"2022","journal-title":"J. Psychopharmacol. (Suppl. )"},{"key":"10.1016\/j.phrs.2025.107727_bib185","first-page":"2","article-title":"Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review","volume":"44","author":"Arsenault-Mehta","year":"2024"},{"key":"10.1016\/j.phrs.2025.107727_bib186","article-title":"Naturally occurring acetylcholinesterase inhibitors and their potential use for Alzheimer\u2019s disease therapy","volume":"9","author":"Dos Santos","year":"2018"},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib187","first-page":"303","article-title":"Cholinesterase Inhibitors as Adjunctive Therapy in Patients with Schizophrenia and Schizoaffective Disorder A Review and Meta-Analysis of the Literature CNS","volume":"24","author":"Ribeiz","year":"2010","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.phrs.2025.107727_bib188","article-title":"Acetylcholinesterase inhibitors for schizophrenia","volume":"2012","author":"Singh","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"20","key":"10.1016\/j.phrs.2025.107727_bib189","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.2174\/138161206777698909","article-title":"Serotonin and Human Cognitive Performance","volume":"12","author":"Schmitt","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2025.107727_bib190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051649","article-title":"Serotonin in animal cognition and behavior","author":"Bacqu\u00e9-cazenave","year":"2020"},{"key":"10.1016\/j.phrs.2025.107727_bib191","first-page":"210","article-title":"Role of serotonin in memory impairment","volume":"32","author":"Buhot","year":"2000"},{"issue":"5","key":"10.1016\/j.phrs.2025.107727_bib192","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1021\/cr078224o","article-title":"Serotonin receptors","volume":"108","author":"Nichols","year":"2008","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib193","article-title":"5-Hydroxytryptamine receptors in GtoPdb v.2023.1","volume":"2023","author":"Andrade","year":"2023","journal-title":"IUPHAR\/BPS Guide Pharmacol. CITE"},{"key":"10.1016\/j.phrs.2025.107727_bib194","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1569-7339(10)70074-6","article-title":"Distribution of 5-HT receptors in the central nervous system","author":"Mengod","year":"2010","journal-title":": Handb. Behav. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib195","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.s1-17.68.289","article-title":"Oriuuatnal 1apers an enquiry into the causes of mescal visions","author":"Marshall","year":"1937","journal-title":"J. Neurol. Psychopathology"},{"key":"10.1016\/j.phrs.2025.107727_bib196","series-title":"Handbook of the Behavioral Neurobiology of Serotonin","first-page":"711","article-title":"Serotonin and Schizophrenia","author":"Quednow","year":"2020"},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib197","doi-asserted-by":"crossref","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","article-title":"Brain mechanisms of hallucinogens and entactogens","volume":"3","author":"Vollenweider","year":"2001","journal-title":"Dialog-. Clin. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib198","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.tins.2008.12.005","article-title":"Psychedelics and schizophrenia","volume":"32","author":"Gonz\u00e1lez-Maeso","year":"2009","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib199","first-page":"59","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011"},{"key":"10.1016\/j.phrs.2025.107727_bib200","first-page":"233","article-title":"Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies","volume":"45","author":"Selvaraj","year":"2014"},{"issue":"9","key":"10.1016\/j.phrs.2025.107727_bib201","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162997","article-title":"Cloning and characterization of novel testis-specific diacylglycerol kinase \u03b7 splice variants 3 and 4","volume":"11","author":"Murakami","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.phrs.2025.107727_bib202","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/mp.2009.33","article-title":"Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia","volume":"15","author":"Yao","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib203","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00431959","article-title":"Brain tryptophan metabolism in schizophrenia: a post mortem study of metabolites on the serotonin and kynurenine pathways in schizophrenic and control subjects","volume":"62","author":"Joseph","year":"1979","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.phrs.2025.107727_bib204","volume":"14","author":"Breier","year":"1995"},{"key":"10.1016\/j.phrs.2025.107727_bib205","article-title":"Serotonrn-dopamine interaction and its relevance to schizophrenia","volume":"53","author":"Kapur","year":"1996","journal-title":"Am. J. Psychiatry I"},{"key":"10.1016\/j.phrs.2025.107727_bib206","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/333174a0","article-title":"Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra","volume":"333","author":"Nedergaard","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107727_bib207","first-page":"445","article-title":"Serotonin research: Contributions to understanding psychoses","volume":"29","author":"Geyer","year":"2008"},{"issue":"5","key":"10.1016\/j.phrs.2025.107727_bib208","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.biopsych.2003.11.016","article-title":"Decreased 5-HT1A receptor binding in amygdala of schizophrenia","volume":"55","author":"Yasuno","year":"2004","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.phrs.2025.107727_bib209","first-page":"305","article-title":"Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia","volume":"18","author":"Silver","year":"2003","journal-title":"Int Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107727_bib210","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4088\/JCP.v68n0417","article-title":"Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis","volume":"68","author":"Sepehry","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib211","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/pr.118.015552","article-title":"International union of basic and clinical pharmacology. Cx. Classification of receptors for 5-hydroxytryptamine; pharmacology and function","volume":"73","author":"Barnes","year":"2021","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.phrs.2025.107727_bib212","first-page":"3068","volume":"10","author":"Shah","year":"2019"},{"key":"10.1016\/j.phrs.2025.107727_bib213","first-page":"177","volume":"31","author":"Taylor","year":"2017"},{"key":"10.1016\/j.phrs.2025.107727_bib214","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-024-03209-1","article-title":"Analysis of clinical studies on clozapine from 2012-2022","author":"Freib\u00fcchler","year":"2024","journal-title":"Naunyn Schmiede Arch. Pharm."},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib215","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00406-023-01654-2","article-title":"A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia","volume":"274","author":"Dong","year":"2024","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.phrs.2025.107727_bib216","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib217","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF02191543","article-title":"A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study","volume":"245","author":"M\u00f6ller","year":"1995","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib218","article-title":"Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib219","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-199511000-00001","article-title":"Risperidone in the treatment of negative symptoms of schizophrenia a meta-analysis","volume":"10","author":"Carman","year":"1995","journal-title":"Int Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107727_bib220","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo","volume":"35","author":"Leucht","year":"1999"},{"issue":"26","key":"10.1016\/j.phrs.2025.107727_bib221","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.2174\/1381612821666150605105215","article-title":"Serotonin 5-HT1A receptors and antipsychotics - an update in light of new concepts and drugs","volume":"21","author":"McCreary","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib222","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/pr.118.015552","article-title":"International union of basic and clinical pharmacology. Cx. Classification of receptors for 5-hydroxytryptamine; pharmacology and function","volume":"73","author":"Barnes","year":"2021","journal-title":"Pharm. Rev."},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib223","first-page":"531","volume":"73","author":"Burnet","year":"1996","journal-title":"Effects of Clozapine Haloperidol on serotonin-1A,-2A -2C Receptor gene\u00a0expression and serotonin metabolism in the rat forebain."},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib224","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-006-0543-8","article-title":"Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635","volume":"189","author":"Frankle","year":"2006","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib225","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1017\/S1461145704004663","article-title":"Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology","volume":"7","author":"Huang","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib226","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s12031-012-9928-9","article-title":"Relationship between genetic polymorphisms in the HTR1A gene and paranoid schizophrenia in a Northern Han Chinese population","volume":"49","author":"Zhou","year":"2013","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib227","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbr.2008.05.016","article-title":"Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?","volume":"195","author":"Meltzer","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib228","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbr.2008.02.023","article-title":"The role of 5-HT1A receptors in learning and memory","volume":"195","author":"\u00d6gren","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2025.107727_bib229","volume":"1","author":"Meldrum","year":"2000","journal-title":"Glutamate Glutamine Brain Glutamate a Neurotransm. Brain: Rev. Physiol. Pathol."},{"key":"10.1016\/j.phrs.2025.107727_bib230","first-page":"1469","article-title":"Structure, function, and pharmacology of glutamate receptor ion channels","volume":"73","author":"Hansen","year":"2021","journal-title":"Pharmacol. Rev. Am. Soc. Pharmacol. Exp. Ther. (ASPET)"},{"key":"10.1016\/j.phrs.2025.107727_bib231","doi-asserted-by":"crossref","DOI":"10.1146\/annurev.neuro.23.1.649","article-title":"An evaluation of the hypothesis","volume":"23","author":"Martin","year":"2000","journal-title":"Annu. Rev. Neurosci."},{"issue":"6945","key":"10.1016\/j.phrs.2025.107727_bib232","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature01796","article-title":"Topography and synaptic shaping of direction selectivity in primary auditory cortex","volume":"424","author":"Zhang","year":"2003","journal-title":"Nature"},{"issue":"1-2","key":"10.1016\/j.phrs.2025.107727_bib233","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-4328(02)00272-3","article-title":"Glutamate receptor function in learning and memory","volume":"140","author":"Riedel","year":"2003","journal-title":"Behav. Brain. Res."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib234","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1152\/physrev.00014.2003","article-title":"Long-Term potentiation and memory","volume":"84","author":"Lynch","year":"2004","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2025.107727_bib235","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nrn1763","article-title":"Metabotropic glutamate receptors in the basal ganglia motor circuit","volume":"6","author":"Conn","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"issue":"7","key":"10.1016\/j.phrs.2025.107727_bib236","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/ijnp\/pyy011","article-title":"Human striatal response to reward anticipation linked to hippocampal glutamate levels","volume":"21","author":"Bossong","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2025.107727_bib237","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10571-006-9062-8","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell. Mol. Neurobiol."},{"issue":"12","key":"10.1016\/j.phrs.2025.107727_bib238","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1176\/appi.ajp.2020.20101481","article-title":"Fifty years of research on Schizophrenia: The ascendance of the Glutamatergic Synapse","volume":"177","author":"Coyle","year":"2020","journal-title":"Am. J Psychiatry."},{"key":"10.1016\/j.phrs.2025.107727_bib239","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.phrs.2025.107727_bib240","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/pcn.12823","article-title":"PCN frontier review PCN glutamate hypothesis in schizophrenia","volume":"73","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib241","first-page":"274","article-title":"Why Hippocampal Glutamate Levels Are Elevated in Schizophrenia","volume":"80","author":"Guo","year":"2023"},{"issue":"6","key":"10.1016\/j.phrs.2025.107727_bib242","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000438675","article-title":"Ketamine-Induced Hallucinations","volume":"48","author":"Powers","year":"2015","journal-title":"Psychopathology"},{"issue":"7510","key":"10.1016\/j.phrs.2025.107727_bib243","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Ripke","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107727_bib244","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/01.gim.0000250507.96760.4b","article-title":"Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: a HuGE review and meta-analysis","volume":"9","author":"Li","year":"2007","journal-title":"Genet. Med."},{"key":"10.1016\/j.phrs.2025.107727_bib245","series-title":"In: European Journal of Pharmacology","first-page":"177","article-title":"The genetics of schizophrenia: Glutamate not dopamine?","author":"Collier","year":"2003"},{"key":"10.1016\/j.phrs.2025.107727_bib246","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tins.2007.03.008","article-title":"D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons","volume":"30","author":"Surmeier","year":"2007","journal-title":"Trends Neurosci."},{"issue":"22","key":"10.1016\/j.phrs.2025.107727_bib247","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1523\/JNEUROSCI.1021-04.2004","article-title":"Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms","volume":"24","author":"Tseng","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib248","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tins.2007.03.003","article-title":"Regulation of firing of dopaminergic neurons and control of goal-directed behaviors","volume":"30","author":"Grace","year":"2007","journal-title":"Trends Neurosci."},{"issue":"5","key":"10.1016\/j.phrs.2025.107727_bib249","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.neuron.2020.06.011","article-title":"VTA glutamate neuron activity drives positive reinforcement absent dopamine co-release","volume":"107","author":"Zell","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2025.107727_bib250","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2012.00195","article-title":"Glutamate neurocircuitry: theoretical underpinnings in: schizophrenia","volume":"3","author":"Schwartz","year":"2012","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2025.107727_bib251","first-page":"3583","article-title":"Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia","volume":"27","author":"Buck","year":"2022"},{"key":"10.1016\/j.phrs.2025.107727_bib252","first-page":"97","article-title":"Glutamate and dopamine in schizophrenia: An update for the 21st century","volume":"29","author":"Howes","year":"2015"},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib253","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00702-020-02292-x","article-title":"Efficacy of adjunctive d-Cycloserine for the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"128","author":"Kuppili","year":"2021","journal-title":"J. Neural Transm."},{"issue":"6","key":"10.1016\/j.phrs.2025.107727_bib254","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.biopsych.2004.12.037","article-title":"D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia","volume":"57","author":"Heresco-Levy","year":"2005","journal-title":"Biol. Psychiatry."},{"issue":"5","key":"10.1016\/j.phrs.2025.107727_bib255","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/ijnp\/pyad011","article-title":"New developments in the treatment of Schizophrenia: An expert roundtable","volume":"26","author":"Kantrowitz","year":"2023","journal-title":"Int. J Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib256","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.biopsych.2023.01.015","article-title":"Dose-Dependent augmentation of neuroplasticity-based auditory learning in Schizophrenia: A double-blind, placebo-controlled, randomized, target engagement clinical trial of the NMDA glutamate receptor agonist D-serine","volume":"94","author":"Sehatpour","year":"2023","journal-title":"Biol. Psychiatry."},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib257","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biopsych.2023.04.022","article-title":"Dose finding for d-Serine enhancement of plasticity in Schizophrenia","volume":"94","author":"Nemani","year":"2023","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib258","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1017\/S1461145709990939","article-title":"A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia","volume":"13","author":"Lane","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib259","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00221-022-06530-4","article-title":"Sarcosine (glycine transporter inhibitor) attenuates behavioural and biochemical changes induced by ketamine, in the rat model of schizophrenia","volume":"241","author":"Kumar","year":"2023","journal-title":"Exp. Brain Res"},{"key":"10.1016\/j.phrs.2025.107727_bib260","volume":"26","author":"Fond","year":"2023"},{"issue":"6","key":"10.1016\/j.phrs.2025.107727_bib261","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib262","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4306\/pi.2017.14.1.63","article-title":"Efficacy and safety of bitopertin in patients with schizophrenia and predominant negative symptoms: Subgroup analysis of Japanese patients from the global randomized phase 2 trial","volume":"14","author":"Hirayasu","year":"2017","journal-title":"Psychiatry Invest."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib263","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","article-title":"Bitopertin in Negative Symptoms of Schizophrenia\u2014Results From the Phase III FlashLyte and DayLyte Studies","volume":"82","author":"Bugarski-Kirola","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib264","first-page":"1557","article-title":"Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia","volume":"273","author":"Rosenbrock","year":"2023"},{"key":"10.1016\/j.phrs.2025.107727_bib265","unstructured":"Boehringer Ingelheim. update-phase-iii-connex-clinical-program-schizophrenia. 2025. https:\/\/www.boehringer-ingelheim.com\/human-health\/mental-health\/schizophrenia\/update-phase-iii-connex-clinical-program-schizophrenia (retrieved 06\/05\/25)."},{"issue":"9","key":"10.1016\/j.phrs.2025.107727_bib266","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib267","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107727_bib268","article-title":"Molecular Brain","volume":"10","author":"Maksymetz","year":"2017"},{"key":"10.1016\/j.phrs.2025.107727_bib269","first-page":"66","article-title":"Perspectives on the mGluR2\/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?","volume":"60","author":"Li","year":"2015"},{"key":"10.1016\/j.phrs.2025.107727_bib270","first-page":"506","article-title":"Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment","volume":"38","author":"Ellaithy","year":"2015"},{"key":"10.1016\/j.phrs.2025.107727_bib271","doi-asserted-by":"crossref","first-page":"40224","DOI":"10.1074\/jbc.R112.386664","article-title":"Structure, function, and modulation of GABAA receptors","volume":"287","author":"Sigel","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107727_bib272","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.drudis.2009.06.009","article-title":"The complexity of the GABAA receptor shapes unique pharmacological profiles","volume":"14","author":"D\u2019Hulst","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2025.107727_bib273","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrd3502","article-title":"Beyond classical benzodiazepines: novel therapeutic potential of GABA A receptor subtypes","volume":"10","author":"Rudolph","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2025.107727_bib274","article-title":"REVIEW Which GABA,-receptor subtypes really occur in the brain? GABA, receptors a heterogeneous family ligand-gated ion responsible for mediating inhibitory","volume":"19","author":"Mckernan","year":"1996","journal-title":"Trends Nurosci"},{"issue":"8","key":"10.1016\/j.phrs.2025.107727_bib275","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2174\/1568026023393507","article-title":"Subunit composition, distribution and function of GABA-A receptor subtypes","volume":"2","author":"Sieghart","year":"2002","journal-title":"Curr. Top. Med Chem."},{"key":"10.1016\/j.phrs.2025.107727_bib276","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrn3249","article-title":"Regulation of neuronal GABAB receptor functions by subunit composition","volume":"13","author":"Gassmann","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib277","series-title":"Physical and Biological Sciences","first-page":"390","article-title":"Diversity of structure and function of GABAB receptors: A complexity of GABAB-mediated signaling","volume":"94","author":"Terunuma","year":"2018"},{"issue":"12","key":"10.1016\/j.phrs.2025.107727_bib278","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00702-019-02080-2","article-title":"Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies","volume":"126","author":"Kaar","year":"2019","journal-title":"J. Neural Transm."},{"issue":"12","key":"10.1016\/j.phrs.2025.107727_bib279","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/cercor\/bhg084","article-title":"Gamma oscillations correlate with working memory load in humans","volume":"13","author":"Howard","year":"2003","journal-title":"Cereb. Cortex"},{"issue":"28","key":"10.1016\/j.phrs.2025.107727_bib280","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1523\/JNEUROSCI.1948-06.2006","article-title":"Theta and gamma oscillations predict encoding and retrieval of declarative memory","volume":"26","author":"Osipova","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib281","first-page":"143","article-title":"Brain oscillations and memory","volume":"20","author":"D\u00fczel","year":"2010"},{"key":"10.1016\/j.phrs.2025.107727_bib282","first-page":"832","article-title":"Gamma oscillations and episodic memory","volume":"46","author":"Griffiths","year":"2023"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib283","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-023-02511-5","article-title":"Alterations of auditory-evoked gamma oscillations are more pronounced than alterations of spontaneous power of gamma oscillation in early stages of schizophrenia","volume":"13","author":"Tada","year":"2023","journal-title":"Transl. Psychiatry"},{"issue":"5","key":"10.1016\/j.phrs.2025.107727_bib284","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/schbul\/sbs010","article-title":"NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia","volume":"38","author":"Gonzalez-Burgos","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107727_bib285","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.nicl.2014.03.007","article-title":"GABA level, gamma oscillation, and working memory performance in schizophrenia","volume":"4","author":"Chen","year":"2014","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.phrs.2025.107727_bib286","series-title":"In: American Journal of Psychiatry","first-page":"1131","article-title":"Pathological basis for deficient excitatory drive to cortical parvalbumin interneurons in schizophrenia","author":"Chung","year":"2016"},{"key":"10.1016\/j.phrs.2025.107727_bib287","article-title":"GABAergic dysfunction in postmortem dorsolateral prefrontal cortex: implications for cognitive deficits in schizophrenia and affective disorders","volume":"18","author":"Hughes","year":"2024"},{"key":"10.1016\/j.phrs.2025.107727_bib288","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.158.2.256","article-title":"Article GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons","volume":"158","author":"Volk","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib289","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.brainresrev.2006.04.001","article-title":"Molecular and cellular mechanisms of altered GAD1\/GAD67 expression in schizophrenia and related disorders","volume":"52","author":"Akbarian","year":"2006","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.phrs.2025.107727_bib290","article-title":"Translational Psychiatry","volume":"7","author":"Egerton","year":"2017"},{"issue":"10","key":"10.1016\/j.phrs.2025.107727_bib291","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamapsychiatry.2023.3157","article-title":"Prefrontal \u03b3-aminobutyric acid levels in never-medicated individuals with chronic schizophrenia","volume":"80","author":"Reyes-Madrigal","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib292","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.neuron.2012.03.026","article-title":"Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner","volume":"74","author":"Schafer","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2025.107727_bib293","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12540","article-title":"Microglia contact induces synapse formation in developing somatosensory cortex","volume":"7","author":"Miyamoto","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107727_bib294","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ibneur.2023.07.005","article-title":"Possible mechanism of schizophrenia origin by excess GABA and synaptic pruning","volume":"15","author":"Rabinovitch","year":"2023","journal-title":"IBRO Neurosci. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib295","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/mp.2012.110","article-title":"Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia","volume":"18","author":"Fillman","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib296","article-title":"Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder- A systematic review of the magnetic resonance neuroimaging literature","volume":"3","author":"Birur","year":"2017"},{"key":"10.1016\/j.phrs.2025.107727_bib297","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.psychres.2017.06.063","article-title":"Z-drug for schizophrenia: a systematic review and meta-analysis","volume":"256","author":"Kishi","year":"2017","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.phrs.2025.107727_bib298","first-page":"733","article-title":"GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia","volume":"39","author":"Xu","year":"2018"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib299","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bpsgos.2021.12.010","article-title":"Hippocampal \u03b15-GABAA receptors modulate dopamine neuron activity in the rat ventral tegmental area","volume":"3","author":"Perez","year":"2023","journal-title":"Biol. Psychiatry Glob. Open Sci."},{"issue":"14","key":"10.1016\/j.phrs.2025.107727_bib300","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411588","article-title":"GL-II-73, a positive allosteric modulator of \u03b15GABAA receptors, reverses dopamine system dysfunction associated with pilocarpine-induced temporal lobe epilepsy","volume":"24","author":"McCoy","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib301","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archgenpsychiatry.2010.114","article-title":"Altered expression of regulators of the cortical chloride transporters NKCC1 and KCC2 in schizophrenia","volume":"68","author":"Arion","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.phrs.2025.107727_bib302","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1021\/acsmedchemlett.5b00181","article-title":"Discovery of VU0409551\/JNJ-46778212: an mGlu5 positive allosteric modulator clinical candidate targeting schizophrenia","volume":"6","author":"Conde-Ceide","year":"2015","journal-title":"ACS Med Chem. Lett."},{"key":"10.1016\/j.phrs.2025.107727_bib303","doi-asserted-by":"crossref","DOI":"10.2174\/1568026611313010005","article-title":"Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks","volume":"13","author":"Menniti","year":"2013","journal-title":"Curr. Top. Med Chem."},{"key":"10.1016\/j.phrs.2025.107727_bib304","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neubiorev.2012.12.005","article-title":"Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia","volume":"37","author":"Matosin","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.phrs.2025.107727_bib305","first-page":"275","article-title":"Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia","volume":"101","author":"Dogra","year":"2022"},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib306","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3390\/molecules16032097","article-title":"Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders","volume":"16","author":"Cleva","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2025.107727_bib307","first-page":"240","article-title":"Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors","volume":"40","author":"Stansley","year":"2019"},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib308","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.neuron.2015.03.063","article-title":"Biased mGlu5-Positive Allosteric Modulators Provide InVivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents","volume":"86","author":"Rook","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2025.107727_bib309","series-title":"T292. RL-007, A NOVEL ORAL NEUROMODULATOR BEING DEVELOPED TO TREAT COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA \u2013 A NON-CLINICAL AND CLINICAL OVERVIEW. In: SIRS abstracts book","author":"McEwen","year":"2024"},{"issue":"26","key":"10.1016\/j.phrs.2025.107727_bib310","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib311","doi-asserted-by":"crossref","first-page":"83","DOI":"10.9758\/cpn.2015.13.1.83","article-title":"The influence of Levetiracetam in cognitive performance in healthy individuals: neuropsychological, behavioral and electrophysiological approach","volume":"13","author":"Magalh\u00e3es","year":"2015","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib312","first-page":"13","article-title":"SDI-118, a novel procognitive SV2A modulator: first-in-human randomized controlled trial including PET\/fMRI assessment of target engagement","author":"Botermans","year":"2023","journal-title":"Front Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib313","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/archpsyc.1988.01800260109013","article-title":"Adult Schizophrenia Following Prenatal Exposure to an Influenza Epidemic","volume":"45","author":"Mednick","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib314","doi-asserted-by":"crossref","DOI":"10.1001\/archpsyc.61.8.774","article-title":"Serologic evidence of prenatal influenza in the etiology of schizophrenia","volume":"61","author":"Brown","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib315","article-title":"Maternal Immune Activation and Schizophrenia\u2013Evidence for an Immune Priming Disorder","volume":"12","author":"Choudhury","year":"2021"},{"key":"10.1016\/j.phrs.2025.107727_bib316","article-title":"Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives","volume":"13","author":"Ermakov","year":"2022"},{"key":"10.1016\/j.phrs.2025.107727_bib317","first-page":"6","article-title":"Inflammation in first-episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis","volume":"146","author":"Dunleavy","year":"2022"},{"key":"10.1016\/j.phrs.2025.107727_bib318","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.schres.2024.02.001","article-title":"Inflammatory cerebrospinal fluid markers in schizophrenia spectrum disorders: a systematic review and meta-analysis of 69 studies with 5710 participants","volume":"266","author":"Warren","year":"2024","journal-title":"Schizophr. Res"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib319","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13003","article-title":"Microglia activation in postmortem brains with schizophrenia demonstrates distinct morphological changes between brain regions","volume":"32","author":"Gober","year":"2022","journal-title":"Brain Pathol."},{"issue":"13","key":"10.1016\/j.phrs.2025.107727_bib320","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1017\/S0033291718003057","article-title":"Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies","volume":"49","author":"Marques","year":"2019","journal-title":"Psychol. Med"},{"issue":"1\u20133","key":"10.1016\/j.phrs.2025.107727_bib321","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.schres.2010.07.001","article-title":"Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data","volume":"122","author":"Jia","year":"2010","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107727_bib322","first-page":"14","article-title":"Schizophrenia Research","volume":"176","author":"Watkins","year":"2016"},{"key":"10.1016\/j.phrs.2025.107727_bib323","article-title":"Translational Psychiatry","volume":"7","author":"Howes","year":"2017"},{"issue":"5","key":"10.1016\/j.phrs.2025.107727_bib324","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/schbul\/sby024","article-title":"Inflammation in schizophrenia: Pathogenetic aspects and therapeutic considerations","volume":"44","author":"M\u00fcller","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107727_bib325","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/s41386-023-01760-8","article-title":"A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-na\u00efve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms","volume":"49","author":"Wang","year":"2024","journal-title":"Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib326","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","article-title":"Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An update","volume":"40","author":"Sommer","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107727_bib327","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-clinpsy-081122-013201","article-title":"Immune Dysfunction in Schizophrenia Spectrum Disorders","volume":"125","author":"Gangadin","year":"2024","journal-title":"Annu Rev. Clin. Psychol."},{"key":"10.1016\/j.phrs.2025.107727_bib328","first-page":"2307","article-title":"Psychological Medicine","volume":"49","author":"\u00c7akici","year":"2019"},{"key":"10.1016\/j.phrs.2025.107727_bib329","first-page":"364","article-title":"Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders \u2013 A comprehensive systematic review and meta-analysis","volume":"90","author":"Jeppesen","year":"2020"},{"issue":"11","key":"10.1016\/j.phrs.2025.107727_bib330","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2215-0366(18)30345-6","article-title":"The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Deakin","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib331","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.schres.2018.10.023","article-title":"The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial","volume":"206","author":"Weiser","year":"2019","journal-title":"Schizophr. Res"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib332","doi-asserted-by":"crossref","first-page":"8","DOI":"10.24869\/psyd.2023.8","article-title":"Monoclonal antibody therapy in autoanyibody-associated psychotic disorders and schizophrenia: narrative review of past and current clinical trials","volume":"35","author":"Niels Hansen","year":"2023","journal-title":"Psychiatria Danubina"},{"key":"10.1016\/j.phrs.2025.107727_bib333","author":"Tikka","year":"2001","journal-title":"Minocycline, a Tetracycline Deriv., Is. Neuroprotective Excit. Inhib. Act. Prolif. Micro"},{"key":"10.1016\/j.phrs.2025.107727_bib334","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbi.2023.12.036","article-title":"Association between doxycycline use and long-term functioning in patients with schizophrenia","volume":"117","author":"de Witte","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.phrs.2025.107727_bib335","article-title":"Minocycline as treatment for psychiatric and neurological conditions: a systematic review and meta-analysis","volume":"24","author":"Panizzutti","year":"2023","journal-title":"Int. J. Mol. Sci. Multidiscip. Digit. Publ. Inst. (MDPI)"},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib336","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41593-018-0334-7","article-title":"Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning","volume":"22","author":"Sellgren","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib337","first-page":"290","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014"},{"key":"10.1016\/j.phrs.2025.107727_bib338","first-page":"770","article-title":"Therapeutic targeting of 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases: inhibition and beyond","volume":"18","author":"Baillie","year":"2019"},{"key":"10.1016\/j.phrs.2025.107727_bib339","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pbb.2011.03.022","article-title":"Drug targets for cognitive enhancement in neuropsychiatric disorders","volume":"99","author":"Wallace","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"11","key":"10.1016\/j.phrs.2025.107727_bib340","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1177\/0271678X17720868","article-title":"Quantification of human brain PDE4 occupancy by GSK356278: a [11C](R)-rolipram PET study","volume":"38","author":"van der Aart","year":"2018","journal-title":"J. Cereb. Blood Flow. Metab."},{"issue":"5","key":"10.1016\/j.phrs.2025.107727_bib341","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00213-018-5134-y","article-title":"An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients","volume":"238","author":"Gilleen","year":"2021","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.phrs.2025.107727_bib342","first-page":"1201","article-title":"Psychopharmacology","volume":"240","author":"Sadeghi","year":"2023"},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib343","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/schbul\/sbac181","article-title":"Positron emission tomography assessments of phosphodiesterase 10A in patients with schizophrenia","volume":"49","author":"Kubota","year":"2023","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.phrs.2025.107727_bib344","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1176\/appi.ajp.2015.15040518","article-title":"Phosphodiesterase 10A in schizophrenia: A PET study using [11C]IMA107","volume":"173","author":"Marques","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib345","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/tp.2017.11","article-title":"Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: A PET and MRI study","volume":"7","author":"Bod\u00e9n","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib346","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0000000000001047","article-title":"A proof-of-concept study evaluating the phosphodiesterase 10A Inhibitor PF-02545920 in the adjunctive treatment of suboptimally controlled symptoms of schizophrenia","volume":"39","author":"Demartinis","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107727_bib347","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.schres.2018.08.028","article-title":"A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia","volume":"204","author":"Macek","year":"2019","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107727_bib348","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.schres.2024.05.019","article-title":"Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: a randomized proof-of-concept clinical trial","volume":"270","author":"Mukai","year":"2024","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107727_bib349","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjp.0706495","article-title":"Phosphodiesterase inhibitors","volume":"147","author":"Boswell-Smith","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib350","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.neuropharm.2011.08.008","article-title":"Selective phosphodiesterase inhibitors improve performance on the ED\/ID cognitive task in rats","volume":"62","author":"Rodefer","year":"2012","journal-title":"Neuropharmacology"},{"issue":"1\u20133","key":"10.1016\/j.phrs.2025.107727_bib351","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00213-008-1278-5","article-title":"A placebo-controlled study of sildenafil effects on cognition in schizophrenia","volume":"202","author":"Goff","year":"2009","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.phrs.2025.107727_bib352","article-title":"PDE10A Inhibitors\u2014Clinical Failure or Window Into Antipsychotic Drug Action?","volume":"14","author":"Menniti","year":"2021"},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib353","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1021\/acs.jmedchem.2c01521","article-title":"Discovery of MK-8189, a highly potent and selective PDE10A inhibitor for the treatment of schizophrenia","volume":"66","author":"Layton","year":"2023","journal-title":"J. Med Chem."},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib354","doi-asserted-by":"crossref","first-page":"103391","DOI":"10.1016\/j.jpet.2025.103391","article-title":"The long and winding road of schizophrenia drug development","volume":"392","author":"Huang","year":"2025","journal-title":"J. Pharm. Exp. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib355","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/schbul\/sby049","article-title":"Evaluation of the efficacy, safety, and tolerability of bi 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia: a randomized, double-blind, placebo-controlled, phase II trial","volume":"45","author":"Brown","year":"2019","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib356","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrn1034","article-title":"The role of histamine and the tuberomamillary nucleus in the nervous system","volume":"4","author":"Haas","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib357","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1124\/pr.114.010249","article-title":"International union of basic and clinical pharmacology. XCVIII. histamine receptors","volume":"67","author":"Panula","year":"2015","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.phrs.2025.107727_bib358","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrn3526","article-title":"The histaminergic network in the brain: basic organization and role in disease","volume":"14","author":"Panula","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2025.107727_bib359","doi-asserted-by":"crossref","unstructured":"Heleniak E., O\u2019Desky I. Histamine and prostaglandins in schizophrenia: revisited. 52(1) (1999 Jan 1) 37-42.","DOI":"10.1054\/mehy.1997.0671"},{"issue":"9","key":"10.1016\/j.phrs.2025.107727_bib360","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"Antipsychotic drug-induced weight gain mediated by histamine H 1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib361","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"HL-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib362","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1476-5381.2009.00149.x","article-title":"Altered histamine H 3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases","volume":"157","author":"Jin","year":"2009","journal-title":"Br. J. Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib363","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.euroneuro.2004.10.001","article-title":"Histamine H1 receptors in schizophrenic patients measured by positron emission tomography","volume":"15","author":"Iwabuchi","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib364","article-title":"Histamine H1 receptor deletion in cholinergic neurons induces sensorimotor gating ability deficit and social impairments in mice","volume":"12","author":"Cheng","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107727_bib365","volume":"41","author":"Molina-Hern\u00e1ndez","year":"2001"},{"key":"10.1016\/j.phrs.2025.107727_bib366","first-page":"11","article-title":"Histamine H3 heteroreceptors suppress glutamatergic and GABAergic synaptic transmission in the rat insular cortex","author":"Takei","year":"2017","journal-title":"Front Neural Circuits"},{"key":"10.1016\/j.phrs.2025.107727_bib367","first-page":"74","volume":"106","author":"Bolam","year":"2016"},{"issue":"12","key":"10.1016\/j.phrs.2025.107727_bib368","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1038\/npp.2009.89","article-title":"H 3 receptor antagonism enhances NCAM PSA-mediated plasticity and improves memory consolidation in odor discrimination and delayed match-to-position paradigms","volume":"34","author":"Foley","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib369","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyae011","article-title":"Histamine-3 receptor availability and glutamate levels in the brain: a PET-1H-MRS study of patients with schizophrenia and healthy controls","volume":"27","author":"Arumuham","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib370","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajp.2014.08.005","article-title":"Role of ranitidine in negative symptoms of schizophrenia - an open label study","volume":"12","author":"Mehta","year":"2014","journal-title":"Asian J. Psychiatr."},{"issue":"4","key":"10.1016\/j.phrs.2025.107727_bib371","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/JCP.0b013e3182970490","article-title":"A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia","volume":"33","author":"Meskanen","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib372","first-page":"30","article-title":"Efficacy and tolerability of histamine-2 receptor antagonist adjunction of antipsychotic treatment in schizophrenia: a meta-analysis of randomized placebo-controlled trials","volume":"48","author":"Kishi","year":"2015","journal-title":"Pharmacopsychiatry"},{"issue":"9","key":"10.1016\/j.phrs.2025.107727_bib373","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207003120","article-title":"Histamine H2 receptor deficit in glutamatergic neurons contributes to the pathogenesis of schizophrenia","volume":"120","author":"Ma","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib374","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1570159X19666210909144930","article-title":"Changes in Histaminergic System in Neuropsychiatric Disorders and the Potential Treatment Consequences","volume":"20","author":"Shan","year":"2022","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib375","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.111.186585","article-title":"CEP-26401 (Irdabisant), a potent and selective histamine H 3 receptor antagonist\/inverse agonist with cognition-enhancing and wake-promoting activities","volume":"340","author":"Raddatz","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.phrs.2025.107727_bib376","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.bcp.2007.01.023","article-title":"Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649","volume":"73","author":"Ligneau","year":"2007","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.phrs.2025.107727_bib377","first-page":"1103","article-title":"The challenge of drug discovery of a GPCR target: Analysis of preclinical pharmacology of histamine H3 antagonists\/inverse agonists","volume":"71","author":"Hancock","year":"2006"},{"key":"10.1016\/j.phrs.2025.107727_bib378","article-title":"The case for TAAR1 as a modulator of central nervous system function","volume":"8","author":"Rutigliano","year":"2018"},{"key":"10.1016\/j.phrs.2025.107727_bib379","article-title":"TAAR1 as an emerging target for the treatment of psychiatric disorders","volume":"253","author":"Liu","year":"2024"},{"key":"10.1016\/j.phrs.2025.107727_bib380","first-page":"183","article-title":"Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities","volume":"5","author":"Nair","year":"2022"},{"issue":"16","key":"10.1016\/j.phrs.2025.107727_bib381","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A non\u2013D2-receptor-binding drug for the treatment of schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107727_bib382","first-page":"1543","article-title":"Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia","volume":"273","author":"Achtyes","year":"2023"},{"key":"10.1016\/j.phrs.2025.107727_bib383","first-page":"503","article-title":"The trace amine-associated receptor 1 agonists \u2013 non-dopaminergic antipsychotics or covert modulators of D2 receptors?","volume":"38","author":"Reynolds","year":"2024"},{"issue":"2","key":"10.1016\/j.phrs.2025.107727_bib384","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"10.1016\/j.phrs.2025.107727_bib385","article-title":"Latent inhibition and its potential as a biomarker for schizophrenia","volume":"3","author":"Granger","year":"2020"},{"issue":"6679","key":"10.1016\/j.phrs.2025.107727_bib386","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1126\/science.adg8538","article-title":"Illusory generalizability of clinical prediction models","volume":"383","author":"Chekroud","year":"2024","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2025.107727_bib387","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-022-01916-y","article-title":"Large-scale real-world data analysis identifies comorbidity patterns in schizophrenia","volume":"12","author":"Lu","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.phrs.2025.107727_bib388","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamapsychiatry.2021.3990","article-title":"Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials","volume":"79","author":"Taipale","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib389","article-title":"MicroRNA schizophrenia: Etiology, biomarkers and therapeutic targets","volume":"146","author":"Zhang","year":"2023"},{"key":"10.1016\/j.phrs.2025.107727_bib390","first-page":"509","article-title":"Neuroimaging Biomarkers in Schizophrenia","volume":"178","author":"Kraguljac","year":"2021"},{"issue":"7","key":"10.1016\/j.phrs.2025.107727_bib391","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1021\/acs.jproteome.4c00040","article-title":"Protein profiles and novel molecular biomarkers of schizophrenia based on 4D-DIA proteomics","volume":"23","author":"Shen","year":"2024","journal-title":"J. Proteome Res"},{"key":"10.1016\/j.phrs.2025.107727_bib392","article-title":"Bridging the gaps towards precision psychiatry: Mechanistic biomarkers for early detection and intervention","volume":"321","author":"Do","year":"2023"},{"key":"10.1016\/j.phrs.2025.107727_bib393","article-title":"Measuring functional outcomes in schizophrenia in an increasingly digital world","volume":"29","author":"Searle","year":"2022"},{"key":"10.1016\/j.phrs.2025.107727_bib394","article-title":"Article meta-regression analysis of placebo response in antipsychotic trials","volume":"170","author":"Agid","year":"1970","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107727_bib395","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.schres.2018.05.009","article-title":"60\u00a0years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response","volume":"201","author":"Leucht","year":"2018","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107727_bib396","first-page":"605","article-title":"The Placebo Effect in Psychosis: Why It Matters and How to Measure It","volume":"3","author":"Hird","year":"2023"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825001525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825001525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T22:46:48Z","timestamp":1750200408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825001525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":395,"alternative-id":["S1043661825001525"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107727","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IUPHAR review: Moving beyond dopamine-based therapeutic strategies for schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107727"}}